Cowen Downgrades Orphazyme A/S (ORPHA:DC) (ORPH) to Market Perform, After Receiving FDA CRL

June 18, 2021 3:54 PM EDT
Get Alerts ORPH Hot Sheet
Price: $4.42 --0%

Rating Summary:
    2 Buy, 0 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 36
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Ritu Baral downgraded Orphazyme A/S (ORPHA:DC) (NASDAQ: ORPH) from Outperform to Market Perform.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Downgrades, Intl Ratings

Related Entities

Cowen & Co, FDA